{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.1","upperLimit":"17.5","value":"14.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"For those subjects with Independent Radiology Committee (IRC) determined Objective Response Rate (ORR), the amount of time from documentation of Objective Response (OR) until Progressive Disease (PD) by mRECIST or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"XL184 175 mg L-malate salt weight; 138 mg freebase equivalent weight, oral capsules once daily","id":"OG000","title":"XL184 (Cabozantinib)"},{"description":"Oral capsules once daily","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"The primary analysis of Objective Response Rate (ORR) was performed among the subset of Intent To Treat (ITT) subjects with measurable disease at baseline and was based upon response as determined by the Independent Review Committee (IRC.) Subjects who did not have post-baseline adequate tumor assessments were counted as nonresponders.","reportingStatus":"POSTED","timeFrame":"From time of first documentation of Objective Response (OR), confirmed at a later visit ≥28 days later as Progressive Disease (PD) as defined by mRECIST or death due to any cause, assessed up to 34 months.","title":"Duration of Objective Response (OR): Independent Radiology Committee (IRC) Determined","type":"SECONDARY","unitOfMeasure":"months"}